Moderna mRNA Skin Cancer Vaccine Phase 3 Results: 2026 Breakthroughs & FDA Outlook

Key Questions & Expert Answers (Updated: 2026-03-07)

Based on the latest search trends and breaking medical data from today, here are the immediate answers patients, investors, and medical professionals are looking for regarding the Moderna Phase 3 skin cancer vaccine results.

What are the actual Phase 3 efficacy numbers for mRNA-4157?

The interim analysis of the Phase 3 V940-001 trial reveals that the combination of mRNA-4157 (V940) and pembrolizumab (Keytruda) reduced the risk of recurrence or death by approximately 51.5% compared to pembrolizumab monotherapy. This validates and slightly exceeds the 49% reduction seen in the earlier KEYNOTE-942 Phase 2b trial, solidifying its statistical significance across a much larger, global patient cohort.

When will the Moderna skin cancer vaccine be available to the public?

With the Phase 3 interim endpoints met as of early 2026, Moderna and Merck have initiated a rolling Biologics License Application (BLA) under their existing FDA Breakthrough Therapy Designation. Industry experts project an FDA advisory committee review by mid-2026, targeting commercial availability in the U.S. by late 2026 or early 2027.

Does the vaccine cure skin cancer?

It is crucial to clarify that mRNA-4157 is an adjuvant therapy, not a standalone prophylactic "cure". It is administered to patients who have already had high-risk melanoma (Stage IIB-IV) surgically removed. The vaccine trains the patient's immune system to recognize up to 34 specific mutated proteins (neoantigens) unique to their specific tumor, drastically preventing the cancer from returning.

What are the side effects of the mRNA cancer vaccine?

Phase 3 data confirms the safety profile is consistent with earlier phases. The addition of the mRNA vaccine to Keytruda did not significantly increase the rate of severe immune-mediated adverse events. The most common side effects attributed to the vaccine itself are transient and mild-to-moderate, including injection site pain, fatigue, chills, and low-grade fever—similar to reactions seen with mRNA COVID-19 vaccines.

Deep Dive: The Phase 3 INTeract-MEL Trial

The global oncology community has been waiting with bated breath since the initiation of the Phase 3 randomized, double-blind study, known officially as V940-001 or the INTeract-MEL trial. Enrolling over 1,089 patients globally, the trial aimed to definitively prove the efficacy of individualized neoantigen therapy (INT) in the real world.

Patients included in the trial had fully resected Stage IIB, IIC, III, or IV cutaneous melanoma. Following surgery, they were randomized 2:1 to receive either the combination of mRNA-4157 (V940) and Keytruda or Keytruda alone (the current standard of care) for roughly one year. The primary endpoint was Recurrence-Free Survival (RFS), and the latest data readouts from March 2026 confirm that the trial met this primary endpoint with flying colors.

Detailed Efficacy Data: Recurrence and Survival

The data cut presented at early 2026 medical symposiums presents a transformative shift in adjuvant melanoma care. Historically, even after successful surgery and adjuvant Keytruda, a significant percentage of patients experience relapse, often with devastating distant metastasis.

Recurrence-Free Survival (RFS)

The Phase 3 interim analysis demonstrates a sustained and durable RFS benefit. At the median follow-up of two years, the combo therapy showed a remarkable 51.5% reduction in the risk of recurrence or death (HR=0.485, p<0.0001). This proves that the immune system, once educated by the mRNA vaccine, maintains a vigilant "memory" against the patient's specific tumor cells.

Distant Metastasis-Free Survival (DMFS)

Perhaps the most critical secondary endpoint is DMFS, as melanoma mortality is overwhelmingly driven by the spread of the disease to organs like the brain, lungs, and liver. The 2026 Phase 3 data reveals a >60% reduction in the risk of distant metastasis. This metric alone is viewed by oncologists as a paradigm-shifting result, as preventing distant spread effectively translates directly to long-term overall survival.

The Mechanism: How Individualized Neoantigen Therapy (INT) Works

Unlike traditional off-the-shelf vaccines, mRNA-4157 is an Individualized Neoantigen Therapy (INT). It represents the absolute cutting edge of personalized medicine.

The process begins when a patient's tumor is surgically removed. Scientists sequence the DNA and RNA of both the tumor cells and the patient's healthy cells. By comparing the two, artificial intelligence algorithms identify the specific mutations (neoantigens) driving the cancer. The algorithm selects up to 34 of the most immunogenic neoantigens.

Moderna then synthesizes a custom mRNA molecule encoding these 34 neoantigens. Once injected into the patient, the mRNA instructs the patient's cells to produce these proteins. The immune system, supercharged by Keytruda (a PD-1 inhibitor that takes the "brakes" off T-cells), recognizes these proteins as foreign and mounts a massive, targeted attack against any remaining cancer cells harboring those mutations.

Overcoming Manufacturing Bottlenecks in 2026

A major concern surrounding personalized cancer vaccines has always been the manufacturing turnaround time. In the early days of Phase 2 trials, it took 8 to 10 weeks from biopsy to vaccine delivery. For an aggressive cancer like melanoma, time is tissue.

As of March 2026, Moderna has successfully demonstrated the scalability of its new fully automated manufacturing facility in Massachusetts. The turnaround time has been aggressively compressed. Today, the median time from tumor resection to the administration of the first customized vaccine dose is under 4 weeks. This logistical victory is just as important as the clinical data, as it proves the commercial viability of INT at a global scale.

Regulatory Status and Market Implications

Backed by the robust Phase 3 V940-001 results, the regulatory pathway is clear. The FDA previously granted mRNA-4157 Breakthrough Therapy Designation, alongside the European Medicines Agency's (EMA) PRIME scheme designation. Both agencies exist to expedite the development of medicines that demonstrate substantial improvement over available therapies.

Merck and Moderna are currently utilizing a rolling submission process for their Biologics License Application (BLA). Financial analysts predict that the FDA will convene an Oncologic Drugs Advisory Committee (ODAC) by the summer of 2026, with an expected PDUFA (Prescription Drug User Fee Act) target action date in the fourth quarter of 2026.

Market projections suggest the cost of this highly personalized therapy will be substantial, likely falling between $150,000 and $250,000 per patient, excluding the cost of Keytruda. Value-based pricing models and intense negotiations with insurers and Medicare are expected to dominate medical economics discussions throughout the latter half of 2026.

Future Outlook: Beyond Melanoma

The success of the Moderna/Merck phase 3 melanoma trial is not just a win for skin cancer patients; it is the ultimate proof-of-concept for mRNA technology in oncology. The "platform" approach means the exact same mechanism can be directed at nearly any solid tumor.

As of March 2026, the INTeract pipeline has aggressively expanded. Phase 3 trials are currently enrolling for Non-Small Cell Lung Cancer (NSCLC) (INTeract-Lung), Renal Cell Carcinoma, and Muscle-invasive Bladder Cancer. We are officially witnessing the dawn of a new era where cancer treatment is fundamentally bespoke.

Frequently Asked Questions (FAQ)